Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Solid Biosciences Inc (SLDB)
Solid Biosciences Inc (SLDB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,129
  • Shares Outstanding, K 20,177
  • Annual Sales, $ 8,090 K
  • Annual Income, $ -85,980 K
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.30
Trade SLDB with:

Options Overview Details

View History
  • Implied Volatility 170.74% ( +37.54%)
  • Historical Volatility 90.38%
  • IV Percentile 91%
  • IV Rank 21.67%
  • IV High 770.61% on 10/17/23
  • IV Low 4.77% on 09/26/23
  • Put/Call Vol Ratio 18.80
  • Today's Volume 99
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 3.06
  • Today's Open Interest 2,206
  • Open Int (30-Day) 2,001

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.01
  • Number of Estimates 4
  • High Estimate -0.54
  • Low Estimate -1.35
  • Prior Year -0.68
  • Growth Rate Est. (year over year) -48.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.54 +49.39%
on 02/05/24
10.41 -6.15%
on 02/16/24
+2.68 (+37.80%)
since 02/01/24
3-Month
2.70 +261.85%
on 12/04/23
10.41 -6.15%
on 02/16/24
+6.76 (+224.58%)
since 12/01/23
52-Week
1.81 +439.78%
on 10/30/23
10.41 -6.15%
on 02/16/24
+4.27 (+77.64%)
since 03/01/23

Most Recent Stories

More News
Are Gene Therapy Stocks The Market's Next Big Winners?

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

SRPT : 128.67 (+0.60%)
BMRN : 87.14 (+1.00%)
BIIB : 220.95 (+1.82%)
CRSP : 83.75 (-0.56%)
EDIT : 10.53 (+4.67%)
NTLA : 32.66 (+1.68%)
NVS : 102.06 (+1.08%)
ORTX : 16.70 (+0.30%)
REGN : 982.82 (+1.73%)
SLDB : 9.77 (+4.05%)
BLUE : 1.5650 (+12.59%)
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SLDB : 9.77 (+4.05%)
CLNN : 0.3890 (-3.33%)
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 51.61% and 29.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

YMAB : 18.69 (+11.92%)
SLDB : 9.77 (+4.05%)
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALNY : 152.61 (+1.01%)
SLDB : 9.77 (+4.05%)
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion

Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.

GSK : 42.03 (+0.31%)
BIIB : 220.95 (+1.82%)
GILD : 72.31 (+0.29%)
SLDB : 9.77 (+4.05%)
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug

CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.

BIIB : 220.95 (+1.82%)
GILD : 72.31 (+0.29%)
SLDB : 9.77 (+4.05%)
CINC : 29.06 (-0.48%)
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

BIIB : 220.95 (+1.82%)
GILD : 72.31 (+0.29%)
SLDB : 9.77 (+4.05%)
RCUS : 19.10 (-0.16%)
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.

BIIB : 220.95 (+1.82%)
GILD : 72.31 (+0.29%)
SPPI : 1.0300 (unch)
SLDB : 9.77 (+4.05%)
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”)...

SLDB : 9.77 (+4.05%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SLDB, FCRD, SPNE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

JVA : 1.3301 (+0.77%)
SLDB : 9.77 (+4.05%)
FCRD : 4.54 (-3.61%)
SPNE : 9.54 (+8.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 10.92
2nd Resistance Point 10.51
1st Resistance Point 10.14
Last Price 9.77
1st Support Level 9.36
2nd Support Level 8.95
3rd Support Level 8.58

See More

52-Week High 10.41
Last Price 9.77
Fibonacci 61.8% 7.12
Fibonacci 50% 6.11
Fibonacci 38.2% 5.10
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar